Circulating Vitamin D and Risk of Epithelial Ovarian Cancer

• Published in: Journal of Oncology
• Main Authors: Arslan, Alan A., Clendenen, Tess V., Koenig, Karen L., Hultdin, Johan, Enquist, Kerstin, Ågren, Åsa, Lukanova, Annekatrin, Sjodin, Hubert, Zeleniuch-Jacquotte, Anne, Shore, Roy E., Hallmans, Göran, Toniolo, Paolo, Lundin, Eva
• Format: Text
• Language: English
• Published: Hindawi Publishing Corporation 2009
• Subjects: Research Article; Northern Sweden
• Online Access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2735000; http://www.ncbi.nlm.nih.gov/pubmed/19727412; https://doi.org/10.1155/2009/672492

We conducted a nested case-control study within two prospective cohorts, the New York University Women's Health Study and the Northern Sweden Health and Disease Study, to examine the association between prediagnostic circulating levels of 25-hydroxy vitamin D (25(OH)D) and the risk of subsequent invasive epithelial ovarian cancer (EOC). The 25(OH)D levels were measured in serum or plasma from 170 incident cases of EOC and 373 matched controls. Overall, circulating 25(OH)D levels were not associated with the risk of EOC in combined cohort analysis: adjusted OR for the top tertile versus the reference tertile, 1.09 (95% CI, 0.59–2.01). In addition, there was no evidence of an interaction effect between VDR SNP genotype or haplotype and circulating 25(OH)D levels in relation to ovarian cancer risk, although more complex gene-environment interactions may exist.